Emergent BioSolutions Inc (EBS) FinancialsEBSEmergent BioSolutions Inc

Emergent BioSolutions Inc. (EBS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Commercial Product sales, accounting for 47.9% of total sales, equivalent to $67.50M. Other significant revenue streams include MCM Product sales and Contracts and grants. Understanding this composition is critical for investors evaluating how EBS navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Emergent BioSolutions Inc. maintains a gross margin of 56.69%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 28.25%, while the net margin is -44.42%. These profitability ratios, combined with a Return on Equity (ROE) of -40.29%, provide a clear picture of how effectively EBS converts its operational activities into shareholder value.

In the context of the broader market, EBS competes directly with industry leaders such as RLMD and ENTA. With a market capitalization of $354.30M, it holds a significant position in the sector. When comparing efficiency, EBS's gross margin of 56.69% stands against RLMD's N/A and ENTA's 100.00%. Such benchmarking helps identify whether Emergent BioSolutions Inc. is trading at a premium or discount relative to its financial performance.

Emergent BioSolutions has shown volatile financial performance with a gross margin of 58.56% in Q2 2026, but this is overshadowed by a net loss of $180.2 million in the same quarter. The forward P/E ratio stands at 22.99, suggesting that the stock may be overvalued given the current financial instability.